Goldman Sachs’s Xtant Medical Holdings XTNT Stock Holding History

Goldman Sachs’s Portfolio XTNT Stock Details XTNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-21,034	Closed	-$13.6K	–	6863
2025 Q3	$13.6K	Buy	+21,034	New	+$13.3K	﹤0.01%	6245
2024 Q1	–	Sell	-33,176	Closed	-$37.5K	–	5924
2023 Q4	$37.5K	Buy	33,176 +20,253	+157%	+$23.8K	﹤0.01%	5406
2023 Q3	$14.2K	Buy	+12,923	New	+$13.9K	﹤0.01%	5381
2016 Q4	–	Sell	-1,468	Closed	-$20K	–	7123
2016 Q3	$20K	Buy	+1,468	New	+$27K	﹤0.01%	6757
2015 Q2	–	Sell	-970	Closed	-$48K	–	7464
2015 Q1	$48K	Sell	970 -134	-12%	-$5.39K	﹤0.01%	6705
2014 Q4	$40K	Buy	1,104 +152	+16%	+$6.32K	﹤0.01%	6868
2014 Q3	$51K	Buy	952 +849	+824%	+$56.4K	﹤0.01%	6810
2014 Q2	$8K	Buy	+103	New	+$8.74K	﹤0.01%	6931

Other funds holding XTNT

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return

HIM

Hillsdale Investment Management Toronto, Ontario, Canada $3.68B AUM 62.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs's XTNT Position: Q4 2025 in Review

Goldman Sachs sold out of Xtant Medical Holdings (XTNT) in Q4 2025, closing a stake of 21,034 shares — an estimated $13.6K sold.

Goldman Sachs first reported a position in XTNT in Q2 2014 and held it in 8 quarters. The position peaked at $51K in Q3 2014. 35 funds tracked by Wall St. Rank hold XTNT as of Q4 2025.

Goldman Sachs reported no remaining Xtant Medical Holdings position as of Q4 2025 after selling out during the quarter.
Goldman Sachs sold 21,034 Xtant Medical Holdings shares in Q4 2025, an estimated $13.6K.
Goldman Sachs first reported a position in Xtant Medical Holdings in Q2 2014 and held it in 8 quarters.
Goldman Sachs's Xtant Medical Holdings position peaked at $51K in Q3 2014.
35 funds tracked by Wall St. Rank held Xtant Medical Holdings as of Q4 2025.

Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.